Suppr超能文献

肌肉减少症与心血管疾病:系统评价和荟萃分析。

Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis.

机构信息

Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Department of Anesthesiology, Laboratory of Mitochondria and Metabolism, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

出版信息

J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1183-1198. doi: 10.1002/jcsm.13221. Epub 2023 Apr 1.

Abstract

Sarcopenia is an age-related disease and is often accompanied by other diseases. Now, many studies have shown that cardiovascular diseases (CVDs) may raise the incidence rate of sarcopenia. Therefore, the purpose of this study was to conduct a systematic review and meta-analysis to investigate the prevalence of sarcopenia in patients with CVDs compared with the general population, defined as relatively healthy non-hospitalized subjects. The databases of PubMed, Embase, Medline and Web of Science were searched for eligible studies published up to 12 November 2022. Two assessment tools were used to evaluate study quality and the risk of bias. Statistical analysis was conducted using STATA 14.0 and R Version 4.1.2. Thirty-eight out of the 89 629 articles retrieved were included in our review. The prevalence of sarcopenia ranged from 10.1% to 68.9% in patients with CVDs, and the pooled prevalence was 35% (95% confidence interval [95% CI]: 28-42%). The pooled prevalence of sarcopenia was 32% (95% CI: 23-41%) in patients with chronic heart failure (CHF), 61% (95% CI: 49-72%) in patients with acute decompensated heart failure (ADHF), 43% (95% CI: 2-85%) in patients with coronary artery disease, 30% (95% CI: 25-35%) in patients with cardiac arrhythmia (CA), 35% (95% CI: 10-59%) in patients with congenital heart disease and 12% (95% CI: 7-17%) in patients with unclassed CVDs. However, in the general population, the prevalence of sarcopenia varied from 2.9% to 28.6% and the pooled prevalence was 13% (95% CI: 9-17%), suggesting that the prevalence of sarcopenia in patients with CVDs was about twice compared with the general population. The prevalence of sarcopenia was significantly higher only in patients with ADHF, CHF and CA compared with the general population. There is a positive correlation between CVDs and sarcopenia. The prevalence of sarcopenia is higher in patients with CVDs than that in the general population. With global aging, sarcopenia has brought a heavy burden to individuals and society. Therefore, it is important to identify the populations with high-risk or probable sarcopenia in order to do an early intervention, such as exercise, to counteract or slow down the progress of sarcopenia.

摘要

肌少症是一种与年龄相关的疾病,常伴有其他疾病。现在,许多研究表明心血管疾病(CVDs)可能会提高肌少症的发病率。因此,本研究旨在进行系统评价和荟萃分析,以调查与一般人群(定义为相对健康的非住院患者)相比,CVD 患者中肌少症的患病率。研究人员检索了截至 2022 年 11 月 12 日发表的 PubMed、Embase、Medline 和 Web of Science 数据库中的合格研究。使用 STATA 14.0 和 R Version 4.1.2 两种评估工具评估研究质量和偏倚风险。采用 STATA 14.0 和 R Version 4.1.2 进行统计分析。从 89629 篇文章中筛选出 38 篇纳入本综述。CVD 患者中肌少症的患病率为 10.1%至 68.9%,汇总患病率为 35%(95%置信区间[95%CI]:28-42%)。慢性心力衰竭(CHF)患者肌少症的患病率为 32%(95%CI:23-41%),急性失代偿性心力衰竭(ADHF)患者为 61%(95%CI:49-72%),冠状动脉疾病患者为 43%(95%CI:2-85%),心律失常(CA)患者为 30%(95%CI:25-35%),先天性心脏病患者为 35%(95%CI:10-59%),未分类 CVD 患者为 12%(95%CI:7-17%)。然而,在一般人群中,肌少症的患病率从 2.9%到 28.6%不等,汇总患病率为 13%(95%CI:9-17%),这表明 CVD 患者的肌少症患病率约为一般人群的两倍。仅 ADHF、CHF 和 CA 患者的肌少症患病率明显高于一般人群。CVDs 与肌少症之间存在正相关。CVD 患者的肌少症患病率高于一般人群。随着全球人口老龄化,肌少症给个人和社会带来了沉重的负担。因此,识别高危或可能发生肌少症的人群非常重要,以便及早进行干预,如运动,以阻止或减缓肌少症的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8620/10235887/d670079e88b9/JCSM-14-1183-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验